Converging evidence, including from recent large-scale randomized controlled trials, demonstrates that modern testosterone therapy does not augment cardiovascular risk or mortality. On the contrary, it confers tangible metabolic and quality-of-life advantages, even in advanced age, provided coexistent conditions are addressed concomitantly. Optimal outcomes hinge upon meticulous patient selection, exclusion of contraindications (e.g., active prostate carcinoma or current fertility intention), and vigilant monitoring of prostate health and hematocrit. When applied with discernment, testosterone therapy offers a safe and efficacious means of restoring androgen sufficiency, thereby enhancing male health and well-being in its fullest sense.
Zitzmann et al. (Fri,) studied this question.